Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01072877 | Completed Phase 3 Results DMC

• 1 other identifier: VAP.VV015
• Study Type: interventional
• Target: 279
• Locations: 1 country
• Sites: 20

Brief Summary

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of three different concentrations of an investigational drug, polidocanol injectable foam compared to vehicle (inactive solution) in treating the symptoms and appearance of varicose veins.

Conditions

Varicose Veins

Keywords

Varicose Veins

Outcome Measures

Primary Outcomes (1)

• Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score)

  The 9 varicose vein symptoms were to be assessed and graded on a 6-point (i.e., 0-5) duration scale and an 11-point (i.e., 0-10) intensity scale, and the patient's level of activity for that day was to be assessed and graded on the 6-point (i.e., 0-5) duration scale. The 9 varicose vein symptoms assessed using the e-diary were derived from the first question of the modified Venous Insufficiency Epidemiologic and Economic Study-Quality of Life/Symptoms (VEINES-QOL/Sym) instrument. The VVSymQ is a subset of 5 VEINESQOL/ Sym items that have been determined in earlier studies to be most important to patients (heaviness, achiness, swelling, throbbing, and itching). The daily VVSymQ score is the sum of the duration scores for these 5 symptoms (scores range from 0 to 25, with the lower end of the range being an indicator of less symptom intensity, and the higher end being an indicator of higher intensity). At Visit 2/baseline, Week 8, scores were calculated

  Week 8

Secondary Outcomes (2)

• Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3)

  8 weeks

• Change From Baseline at 8 Weeks Post Treatment in IPR-V3 Score- Physician Photographic Review of Appearance

  8 weeks post treatment

Study Arms (5)

Polidocanol injectable foam 0.125%

EXPERIMENTAL

Polidocanol injectable foam 0.125%

Drug: Polidocanol injectable foam (PEM)

Polidocanol injectable foam 0.5%

EXPERIMENTAL

Polidocanol injectable foam 0.5%

Drug: Polidocanol injectable foam (PEM)

Polidocanol injectable foam 1.0%

EXPERIMENTAL

Polidocanol injectable foam 1.0%

Drug: Polidocanol injectable foam (PEM)

Polidocanol injectable foam 2.0%

EXPERIMENTAL

Polidocanol injectable foam 2.0%

Drug: Polidocanol injectable foam (PEM)

Vehicle

PLACEBO COMPARATOR

Injection of vehicle comparator

Drug: Placebo Vehicle

Interventions

Polidocanol injectable foam (PEM) DRUG

Injection of Polidocanol injectable foam

Polidocanol injectable foam 0.125%; Polidocanol injectable foam 0.5%; Polidocanol injectable foam 1.0%; Polidocanol injectable foam 2.0%

Placebo Vehicle DRUG

Placebo vehicle

Vehicle

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein
• Ability to comprehend and sign an informed consent document and complete study questionnaires in English
• Ability to record symptoms in accordance with the protocol
• Symptomatic varicose veins
• Visible varicose veins

You may not qualify if:

• Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP (clinical, etiologic, anatomic, and pathophysiologic) Classification of Venous Disorders).
• Leg obesity impairing the ability to access the vein to be treated and/or to apply postprocedure compression bandaging and stockings
• Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion
• Deep vein reflux unless clinically insignificant in comparison to superficial reflux
• Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings
• Reduced mobility
• Major surgery, prolonged hospitalization or pregnancy within 3 months of screening
• Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)
• Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions
• Current alcohol or drug abuse
• Pregnant or lactating women
• Women of childbearing potential not using effective contraception
• History of DVT, pulmonary embolism or stroke

Sponsors & Collaborators

• Boston Scientific Corporation: lead

Study Sites (20)

Unknown Facility

Laguna Hills, California, 92653, United States

Location

Unknown Facility

San Diego, California, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20007, United States

Location

Unknown Facility

Aventura, Florida, 33180, United States

Location

Unknown Facility

Bradenton, Florida, 34209, United States

Location

Unknown Facility

Oakbrook Terrace, Illinois, 60181, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48109, United States

Location

Unknown Facility

Kalamazoo, Michigan, 49009, United States

Location

Unknown Facility

Hartsdale, New York, 10530, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

North Tonawanda, New York, 14120, United States

Location

Unknown Facility

Stony Brook, New York, 10530, United States

Location

Unknown Facility

Charlotte, North Carolina, 28207, United States

Location

Unknown Facility

Durham, North Carolina, 27705, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27157, United States

Location

Unknown Facility

Toledo, Ohio, 43606, United States

Location

Unknown Facility

Bend, Oregon, 97701, United States

Location

Unknown Facility

Clarksville, Tennessee, 37040, United States

Location

Unknown Facility

Kirkland, Washington, 98034, United States

Location

Unknown Facility

Spokane, Washington, 99204, United States

Location

Related Publications (1)

• King JT, O'Byrne M, Vasquez M, Wright D; VANISH-1 Investigator Group. Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance. Eur J Vasc Endovasc Surg. 2015 Dec;50(6):784-93. doi: 10.1016/j.ejvs.2015.06.111. Epub 2015 Sep 16.

  PMID: 26384639 DERIVED

MeSH Terms

Conditions

Varicose Veins

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Results Point of Contact

• Title: David Wright MB FRCS
• Organization: BTG International Inc

david.wright@btgplc.com

610-278-1660

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 19, 2010
• First Posted: February 22, 2010
• Study Start: December 1, 2010
• Primary Completion: December 1, 2011
• Study Completion: November 1, 2012
• Last Updated: April 21, 2021
• Results First Posted: May 16, 2014

Record last verified: 2021-04

Locations

US (20)